Table 3—

Phase 2: outcome data in confirmed pulmonary embolism (PE) patients treated as outpatients

End of acute LMWH treatment
 Subjects n157
 Thromboembolic event0 (0; 0.0–2.3)
 Bleeding complications
  Minor bleed0 (0; 0.0–2.3)
  Major bleed0 (0; 0.0–2.3)
 Deaths0 (0; 0.0–2.3)
 Readmission to hospital
  Related0 (0)
  Unrelated3 (1.9)
3 months after start of PE treatment
 Subjects n156
 Thromboembolic event0 (0; 0.0–2.3)
 Bleeding complications
  Minor bleed1 (0.6; 0.0–3.5)
  Major bleed0 (0; 0.0–2.3)
 Deaths3 (1.9; 0.4–5.5)

  • Data are presented as n (%; 95% confidence interval) or n (%), unless otherwise stated. LMWH: low molecular weight heparin.